Mild Hypertension
Conditions
Brief summary
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
Interventions
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Are men and women between 18 and 70 years of age, inclusive 2. Have given signed informed consent to participate in this study 3. Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)
Exclusion criteria
1. Secondary or malignant hypertension 2. Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment 3. Any previous cardiovascular disease other than hypertension 4. Type 1 or 2 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces 24-hour mean ambulatory Systolic Blood Pressure, compared with placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the population dose and exposure response relationships of LY518674 for lowering the mean SBP and DBP during the 24 hour period, using ABPM during a 6 week treatment period | — |
| Evaluate the population dose, exposure, and time response relationships of LY518674 for lowering the mean SBP and DBP during the 8 hour awake period, using ABPM during a 6 week treatment and following cessation of dosing | — |
| Compare the effect of LY518674 on CBPM SBP and DBP with that of placebo | — |
| Determine the duration and consistency of the reduction in BP over the course of a day, relative to placebo, after 6 weeks of treatment with LY518674 when taken once daily | — |
| Evaluate the effects of LY518674, relative to placebo, on plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C, triglycerides (TG), and high-sensitivity C-reactive protein (hsCRP) | — |
| Evaluate the safety and tolerability effects of LY518674, relative to placebo, in patients with mild hypertension | — |
| Determine the percentage of responders to LY518674, relative to placebo, as defined by patients who achieve target BP goals of CBPM SBP <140 mm Hg and/or DBP 90 mm Hg, or a CBPM SBP decrease of at least 10 mm Hg | — |
Countries
Sweden
Outcome results
None listed